Podcasts about Assay

In-utero procedures can yield better long-term outcomes for the baby. However, fetal surgery relies on instruments developed for other disciplines. An early-stage startup in Maryland is developing in-utero instruments to improve outcomes for both fetus and mother.Fetal Therapy Technologies CEO Selena Shirkin joins Key Tech's Andy Rogers for Episode 42 of the MedTech Speed to Data podcast to discuss startup innovation in fetal surgery.Need to knowFetal surgeries carry risks — In addition to uterine damage complicating future pregnancies, 40% of surgeries have a risk of preterm birth.Few specialized tools are used — In the field's forty-year history, the FDA has only approved the Karl Storz Fetoscope for use in fetal surgeries.Off-label device use is widespread — Equipment borrowed from adjacent fields like laparoscopy and neurosurgery weren't indicated for use in the uterus.The nitty-grittyShirkin and Chief Technology Officer Eric McAlexander founded Fetal Therapy Technologies as students in Johns Hopkins University's biomedical engineering graduate program. While shadowing surgeons, they saw how off-label instruments complicated procedures.“I watched a surgeon using a grasper and suture,” Shirkin recalled. “The suture was falling out of the grasper because they didn't fit. It took time in the surgery to make sure that didn't occur.”Observations like these led the team to wonder why the field lacked optimized tools. “As biomedical engineers,” Shirkin says, “we asked ourselves what if we created those purpose-built instruments that actually make these procedures safer?”They quickly ran into the commercial limits of a market as small as fetal surgery. With only one device FDA-approved for in-uterine procedures, surgeons have no choice but to use devices off-label. So Fetal Therapy Technologies is flipping the script by leveraging the broader applications of an instrument designed for fetal surgeries.“In a way, our company solves two problems at once,” Shirkin says. “A company that creates a fetal innovation [that] also raises a much broader market of general microsurgery.”Their first product is a uterine port. “Similar to laparoscopic surgeries,” Shirkin explains, “that involves inserting a port through the abdomen into the uterus. [The new] port is designed to leverage the elastic properties of the uterine environment to make entry safer than the current clinical standard.”For broader commercialization, they aim to demonstrate equivalence to predicate devices and qualify as a 510(k) Class II device following benchtop and animal studies. Approval for fetal surgeries is a longer journey, but the company can build on its data before entering human trials.Data that made the difference:Shirkin offered insights for other students considering an entrepreneurial future in MedTech.Leverage university resources. “We work incredibly closely with the Johns Hopkins Center for Fetal Therapy,” Shirkin says. We've also gotten opportunities from Johns Hopkins Technology Ventures.”Build a network of advisors. “We are supported by a very broad variety of clinical, technical, and business mentors across the Johns Hopkins ecosystem and beyond.”Tap into local funding sources. “There's a lot of collegiate business plan competitions that we've been very successful [raising] non-dilutive funds that way. There are also state-level grants. We just received a Baltimore Innovation Initiative grant.”

AABP executive Director Dr. Fred Gingrich reviews a paper published in The Bovine Practitioner with two of the authors. Joining today are Dr. Greg Habing, professor in the Department of Preventive Medicine at The Ohio State University College of Veterinary Medicine, and Dr. Emily Nogay, clinical assistant professor at The Ohio State University Large Animal Ambulatory Services.  Salmonella Dublin is a host-adapted and zoonotic pathogen affecting many dairy farms. It can be associated with high morbidity and mortality and is often multi-drug resistant which elevates its importance to dairy farmers and veterinarians. Surveillance and diagnostics are an important aspect of managing diseases in our herds. Nogay reviews available diagnostic tests and the advantages and disadvantages of each one. The ELISA test has a sensitivity of 65%, but is used to screen herds for the disease. The objective of this study was to determine if the four U.S. commercially licensed Salmonella vaccines would result in a positive Salmonella Dublin ELISA test result.  We walk through the results of the paper and discuss some of the findings, including the impact of the vaccines on the serum ELISA results and some potential reasons for the ELISA results after vaccination. Habing discusses future opportunities for research on this disease, including the need for better diagnostic tests, including a PCR test to screen herds.  AABP's peer-reviewed journal, The Bovine Practitioner, publishes original research studies, reviews, case series, and case reports intended to provide clinically relevant research to private practicing veterinarians. It is an open access journal and there are no publication fees for submitting authors. Read more about the journal at this link.  The effect of Salmonella vaccination on Salmonella Dublin blood enzyme-linked immunosorbent assay results. Bov Pract. 2025;59(2), 53-60. https://doi.org/10.21423/bpj20259266

Highland Critical Minerals Corp Director Brian Morales joined Steve Darling from Proactive to announce that the company is set to begin an exploration program at its Sy Property, located in the Yathkyed Lake Greenstone Belt in Nunavut. The area is part of the Archean-aged greenstone belts of the Kivalliq Region, which share geological similarities with nearby belts hosting notable deposits such as Ferguson Lake and the Meadowbank and Meliadine gold deposits. Morales explained that the exploration program is scheduled to commence later in October, beginning with a comprehensive review and compilation of existing geological and geophysical data to refine exploration targets and evaluate the company's current claims footprint. The program will also include an on-site geophysics campaign, weather permitting, to identify potential gold mineralization within banded iron formations. The company's broader exploration work, through its wholly owned subsidiary, Highland Red Lake Gold Corp., continues to progress across its portfolio. Recent activities have focused on geological mapping, prospecting, and rock sampling, supported by a drone-based airborne magnetic and LiDAR survey aimed at defining lode gold potential. Bayside Geoscience completed a geological mapping and sampling program at the end of August, collecting 60 grab samples across the Red Lake Gold Claims. Assay results from these samples are expected in Q4 2025. Meanwhile, Rosor Exploration finalized the drone-based LiDAR and magnetic survey in late September, with final data also anticipated in Q4 2025. The insights from both the Sy Property and RLG exploration initiatives will guide Highland's next phase of exploration planning and target generation heading into 2026. #proactiveinvestors #highlandcriticalmineralscorp #cse #hlnd #RedLakeGold #LithiumExploration #MiningCanada #CSEStocks #JuniorMining #GoldExploration #NunavutMining #SpinoutNews #MiningInvesting

Hire world-class accountants and in The Philippines. Visit Outsource Direct to scale your operations with higher flexibility, maximum efficiency and much lower costs.Subscribe to the Business Builders Newsletter for the very best ideas I've discovered on business and personal growth.In Series 10, Episode #94, I interview Sean Mac Fhearraigh, co-founder and Chief Scientific Officer at Assay Genie. Sean shares his journey from academic cancer researcher to successful entrepreneur. We delve into the challenges of transitioning from science to business, raising funds, and growing Assay Genie into a multimillion-euro enterprise. The conversation spans topics like the importance of credibility in the scientific market, the impact of AI on science, and personal sacrifices made along the way.CONNECT WITH CONOR:LinkedInCONNECT WITH SEAN:LinkedInAssay GenieDiscover EO Ireland—part of an international network designed specifically for entrepreneurs. EO Ireland connects business owners for networking, mentorship, and shared learning experiences. Take your business to the next level and join a community of like-minded leaders today at eoireland.org. Empower your entrepreneurial journey!Produced by Jetbooks, Chartered Accountants Ireland.

In this week's episode, we'll learn more about how exogenous CD19 stimulation affects CAR T-cell persistence in B-cell acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy; new algorithms that incorporate sequential rapid immune-assays, intended to improve diagnosis of heparin-induced thrombocytopenia, and resource-adaptive survival prediction models to help guide management of patients with chronic myelomonocytic leukemia.Featured Articles:Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALLSequential combinations of rapid immunoassays for prompt recognition of heparin-induced thrombocytopeniaBLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia

Host: Ryan Quigley Guest: Hallie Blevins, PhD. Guest: Marlene Mimi Maeusli, PhD. With one in three eligible Americans still unscreened for colorectal cancer (CRC), there's an urgent need for noninvasive and affordable alternatives to colonoscopy. A 2025 study published in ACS Sensors introduces a novel aptamer-based colorimetric assay that targets Parvimonas micra—a gut microbe linked to CRC. To learn more, Mr. Ryan Quigley speaks with Drs. Hallie Blevins and Mimi Maeusli about how this technology works, what sets it apart from current testing methods, and why it could play a role in improving early CRC detection. Reference: Feng S, Zhang P, Chen H, et al. Au@Fe3O4 nanoparticle-based colorimetric aptasensor for noninvasive screening of colorectal cancer via detection of Parvimonas micra. ACS Sens. 2025;10(2):1053-1062.

In this episode of GeOCHemISTea, we're joined by Hugh De Souza to explore the evolution of gold analysis; from 4,000-year-old fire assay traditions to disruptive technologies like photon assay. With over 40 years at research and industry analytical labs and deep experience in mineralogy, geochemistry, and lab innovation, Hugh shares his unconventional path into analytical geochemistry, breaks down the physics behind modern methods, and reflects on what the future holds for gold assay. Whether you're a field geo or into analytical chemistry, this one's for you.

North Bay Resources Inc CEO Jared Lazerson talked with Proactive's Stephen Gunnion about the company's progress at its Fran project, including high-grade assay results and operational plans for its Bishop Gold Mill. Lazerson confirmed that North Bay has completed its initial test mining and is seeing encouraging assay results from the surface oxide zone at Fran. “There have been up to multi-ounce assays,” he said, noting that the mineralization appears to expand in several directions and increases with depth. The ore is described as highly mineralized and visibly distinct, with chalcopyrite, galena, and silver present. Lazerson highlighted that operations are already producing results: “Our mill is up and running. We've produced some gold there.” He outlined plans to ship ore to the mill imminently, targeting an initial throughput of 66 tonnes per week, with potential gross revenues of around $75,000 weekly. Costs are currently about $400 per tonne, giving an estimated $600 profit per tonne after refining. Longer term, the company is targeting a 10,000-tonne test permit and evaluating the path toward a large-scale operation. Lazerson said the broader resource could support a 1 million to 2 million tonne processing capacity. The aim is to become a mid-tier producer, with the potential to generate between $50 million and $100 million, depending on gold prices and comparable mine costs. The company is pursuing a dual-path strategy—short-term cash flow from high-grade ore while advancing toward large-scale development. Lazerson emphasized this approach helps avoid “endless dilution,” a risk many early-stage explorers face. Visit Proactive's YouTube channel for more videos, and don't forget to give this one a like, subscribe to the channel, and enable notifications for future content. #GoldMining #NorthBayResources #FranProject #JaredLazerson #GoldAssays #MiningStocks #BishopGoldMill #JuniorMining #PreciousMetals #MiningInvestment

North Bay Resources CEO Jared Lazerson joined Steve Darling from Proactive to announce a new assay result of 0.5 ounces per ton (14 g/t) gold from a massive sulphide outcrop located near Trench B at the company's Fran Gold Project in British Columbia. The gold-bearing zone—measuring approximately 30 meters north-south by 40 meters east-west with a depth exceeding 4 meters—adds further support to the project's bulk tonnage potential. The 5-pound sample was processed by fire assay with atomic absorption at ALS Global in North Vancouver. Lazerson stated that, following the recent identification of a significant bulk tonnage gold deposit and its corresponding resource estimate, the company is moving forward with a dual-track development strategy. This includes using high-grade surface oxide material as feedstock for its Bishop Gold Mill, while also advancing exploration in the infill area between the Main Bullion Alley Zone, East Zone, and the re-established Hilltop (South) Zone. To support the project's next stage, North Bay has begun consulting with a mine engineering firm to evaluate the detailed economics, mine planning, and construction for the bulk tonnage deposit. Lazerson pointed out that comparable mining costs at the nearby Blackwater Gold Mine are around $9 per tonne processed, while the Fran deposit hosts approximately 20 million tonnes grading 0.5 g/t Au (valued at $54/tonne) and 44 million tonnes at 0.3 g/t Au ($32/tonne), underscoring promising economics. The company sees this dual approach as a pathway to near-term production while continuing to expand and de-risk the Fran Gold Project through targeted exploration. #proactiveinvestors #northbayresourcesinc #otc #nbri #PlatinumConcentrate #NorthBayResources #MiningNews #CaliforniaGold #JaredLazerson #GoldRush #ProactiveInvestors #PreciousMetals #MiningUpdates ---#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #PreciousMetals #BulkSampling #DualTrackStrategy #GoldProduction

Linda Hasadsri, M.D., Ph.D., and Huong Cabral, M.S., CGC, explain how Mayo Clinic Laboratories' expanded test panel captures rarer as well as more common genetic causes of hereditary pancreatitis. That information is key to managing patients' enhanced risk for pancreatic cancer.Speaker 4: (00:32) Could you both please tell us a little bit about yourself and your background? Speaker 4: (02:23) Could you please give the audience a brief overview of this assay?  Speaker 4: (03:53) Which patients should have this test, and when should it be performed? Speaker 4: (04:49) What alternative testing options are available, and how do these compare to the new, expanded panel that we're going to be offering? Speaker 4: (08:20)How are the results used in patient care?

This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at ⁠⁠revival-dash-gold.com⁠⁠Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at ⁠⁠equinoxgold.com⁠⁠ Integra is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

Roger Rosmus, Founder, CEO, & Director of Goliath Resources (TSX.V: GOT) (OTCQB: GOTRF), joins me to review the news out today on June 25th  that announced the Company had increased its largest drill program to date, now totaling 60,000 meters with 9 rigs, that is 100% focused on the extensive Surebet high-grade gold discovery on the Golddigger Property located in the Golden Triangle of British Columbia.    The increase to this year's exploration focus is in light of the newly discovered widespread abundant visible gold seen with the naked eye in multiple reduced intrusion related gold (RIRG) dykes, as well as in the calc-silicate altered breccia during the re-logging initiative of core drilled between 2021 – 2024 that significantly expands the area of strong gold potential. We discussed that the bigger drill program is also focused on following up on the positive results from the 2024 drill season, that tapped into even more higher-grade sheer zones at depth, and which has greatly improved the understanding of this large mineralized system that remains open for expansion in all directions.   Over the last 2 months the exploration team went through the process of relogging prior year's drill core, based on the conclusions from the Colorado School Of Mines geological study which confirmed a common causative Reduced Intrusion Related Gold (RIRG) source at the Surebet discovery. On June 23rd, the Company announced Drill hole GD-22-64, which assayed 6.31 g/t AuEq Over 14.35 meters, including 11.36 g/t AuEq Over 7.85 meters from a gold-rich intrusive feeder dyke and this was the first result of 75 drill holes relogged, many of which contain gold visible to the naked eye over broad intervals identified in 2025 so far.    Armed with this understanding that dykes found on the Project have the potential to be mineralized with this intrusive style of gold, this changes how to interpret prior drilling, and how to move forward now drilling through those dykes into other mineralized horizons instead of avoiding them. Roger highlights the tremendous untapped discovery potential at the Golddigger Project in the Golden Triangle of British Columbia.   Wrapping up we discussed the news released on June 18th, which announced that in addition to the bought deal financing that closed earlier in the month of 7,256,500 common shares of the Company at a price of C$3.17 per Charity Flow-Through Share for gross proceeds of C$23,003,103, that it has also closed a concurrent non-brokered financing of 1,281,545 Charity Flow-Through Shares priced at C$3.17 for gross proceeds of C$4,062,500 for a combined total of C$27,065,605 raised for the Company.     If you have any questions for Roger about Goliath Resources, then please email me at Shad@kereport.com and then we'll get those answered or covered in a future interviews.   In full disclosure, Shad is a shareholder of Goliath Resources at the time of this recording and may choose to buy or sell shares at any time.   Click here to follow the latest news from Goliath Resources

John Lieske, M.D., and Sandra Taler, M.D., explain how Mayo Clinic Laboratories' mass spectrometry assay helps evaluate patients for resistant hypertension. The test detects antihypertensive medications in urine, providing evidence of whether patients are absorbing their medications or whether a new treatment approach might be needed. Speaker 3: (00:33) Could you tell us a little about yourselves and your backgrounds? Speaker 3: (01:41) Dr. Taler, could you provide us with a brief background on resistant hypertension? Speaker 3: (03:43) Can you provide a little bit more background on patients who aren't taking their medications? Speaker 3: (05:11) How do physicians currently assess whether patients are taking their medications? Speaker 3: (07:03) Dr. Lieske, could you tell us how this new assay can be used to help physicians manage their patients with hypertension? Speaker 3: (09:43) Dr. Taler, can you tell us how doctors can use this new testing to manage their patients?

Epinephrine auto-injectors, first developed in the 1970s, are the most common emergency treatments for anaphylaxis, often deadly allergic reactions. The limitations of liquid epinephrine and the device's decades-old technology have kept these life-saving devices out of patients' hands. Austin-based startup Windgap Medical, Inc. plans to break these barriers with a more convenient, shelf-stable alternative.In Episode 41 of the MedTech Speed to Data podcast Key Tech's Andy Rogers and Thomas James sit down with Windgap's co-founder and Chief Business Officer, Brent Buchine, to discuss the data-driven development of the company's life-saving technology.Need to know·       Epinephrine auto-injectors are big business — A $1.3 billion market at Windgap's founding, sales of epinephrine auto-injectors exceeded $3.1 billion in 2024.·       Few eligible patients get these life-saving devices — Only 52% of American food allergy patients ever receive prescriptions, and epinephrine auto-injectors are only available in 32% of the world's 195 countries.·       Traditional auto-injectors are relatively large and inconvenient — Only 55% of patients with prescriptions report having immediate access to their auto-injectors.·       Liquid epinephrine is thermally unstable — Doses lose their effectiveness with prolonged heat exposure, forcing patients to refill their prescriptions more frequently.The nitty-grittyBuchine and his co-founders saw an opportunity to make epinephrine delivery more convenient and accessible. “We developed a freeze-dried version of epinephrine to make it more stable and double, if not triple, the shelf life,” Buchine explains.However, lyophilization introduces an extra step in the treatment process. The dried epinephrine must be rehydrated and mixed in a solution before injection.“If you have a rescue product for emergency use, you have to get it very quickly,” Buchine says. “With modest training, you need to make sure people know how to use the product because their life is at risk if it doesn't work.”Windgap's ANDI® platform is a small, highly portable single-dose auto-injector, Buchine explains. “Simply twisting the cap automatically rehydrates that dose in a couple of seconds — no shaking, no swirling required. It's ready to inject by pressing the device next to the injection site.”Windgap and its pharmaceutical clients are still in the commercialization phase, but the company is already looking at the future of complex injectables.“We see that, fundamentally, formulation pipelines are getting more and more challenging,” Buchine says. “You have multiple injections, you have mixing, you have high viscosity/high volume. The conventional options out there are not as suitable anymore. We're solving those problems specifically because we think there's an opportunity to be best in class in that area.”Data that made the difference:Developing combination products is a multi-stakeholder problem. “It's drug, it's device, it's patient, it's prescriber, it's payer. You've got to think about all of those stakeholders along your development.”Get in front of stakeholders to understand the problem. “We did a lot of surveys and uncovered the opportunity. Patients weren't getting prescriptions filled or weren't even going to the doctor to get prescriptions. It was that segment that we spent a lot of time talking to.”Listen to your customers. “We'll talk to pharmaceutical companies [and ask] what are some of the biggest challenges you're facing in your pipeline? And then you just listen. Over time, you look for that recurring theme. That's what really drove our product strategy.”Use data to convince investors. “There was a vastly underserved market. Our ability to communicate that to investors and help them understand the opportunity of taking [at the time] a $1.3 billion business to something substantially above that.”

Joseph Yao, M.D., explains how Mayo Clinic Laboratories' new quantitative assay (Mayo ID: ADVQU) goes beyond qualitative testing to evaluate transplant patients for adenovirus infection. Adenovirus can cause life-threatening disease in immunocompromised transplant patients, especially children.(01:14)Could you give us a brief overview of this assay? (02:06)Can you explain the differences of the qualitative and quantitative methods and why we made the change to a quantitative adenovirus method? (04:00)When is this test typically ordered for transplant patients? Is it used throughout their treatment? (06:56)Could an immunocompromised person be unknowingly infected? (07:31)Is our quantitative method approved for pediatric patients? (08:00)How are the test results used to treat patients?(10:36)What other infections might providers consider alongside adeovirus?

Zak Mir talks to Greg Martyr, Executive Chairman, Capital Metals, in the wake of the mineral sands company approaching mine development stage at the high-grade Taprobane Minerals Project in Sri Lanka, updating on drilling within the northern EL168 area, focusing on the Initial Mining Area of the existing 17.2 Mt Mineral Resource. Capital Metals' Busy and Promising Period Greg Martr opened by reflecting on a particularly active six months for Capital Metals. Since their last update, the company has made significant strides, including a successful transaction with the Ambient Group. Greg expressed enthusiasm about the new doors this partnership has opened, emphasizing that the collaboration is already proving valuable, despite being only two weeks in. Capital Metals also recently completed a rapidly oversubscribed fundraising round, which was closed early to avoid excessive dilution at the 2.5p share price level. Greg noted the strong support from shareholders and hinted at ongoing discussions regarding the potential exercise of options, signaling healthy interest and confidence in the company's trajectory. Drilling Progress and Mineralization Insights One of the most anticipated updates concerned Capital Metals' drilling program within the northern EL168 area, focusing on the Initial Mining Area of the existing 17.2 million tonnes mineral resource. Greg reported the completion of the first phase with 170 holes drilled, totaling just over 1,500 meters. This drilling effort marks a substantial increase in depth compared to the 2016 resource calculations, which averaged only 1.6 meters, whereas the recent drilling averaged about 9 meters per hole, with some extending as far as 15 meters. What stands out in this phase is the continuation of mineralization down to the basement rock in certain locations. While this extended mineralization is not uniform across all holes, the encouraging results point to the potential for a more substantial resource than previously understood. Assay results are expected shortly, which will provide further clarity on the resource's quality and extent. Strategic Partnerships and Market Validation Greg highlighted the initiation of research coverage by Hannam & Partners, a respected name in mining research known for their rigorous analysis. This development represents a significant endorsement for Capital Metals, often seen as a “gold standard” in the sector. The research team's detailed review of Capital Metals' financial models has already led to improvements in the Net Present Value (NPV) calculations, with an updated model currently being finalized. The company's relatively low capital expenditure (capex) requirements further enhance its appeal. As mineralization increases, the economics of the project improve, making it more cost-effective to extract the resources. This combination of low capex and growing resource size is a powerful advantage as Capital Metals moves toward its investment decision. Favorable Market and Geopolitical Landscape Discussing the broader market context, Greg noted that the project's sector is largely insulated from the ongoing tariffs and export restrictions affecting other industries, particularly Sri Lanka's garment sector. While the garment industry faces uncertainty, the resource sector is gaining increasing importance for foreign investment in Sri Lanka. This shift benefits Capital Metals by positioning it favorably in the eyes of investors and policymakers alike. Share Price Performance and Future Outlook Despite the complexities of the market, Capital Metals' shares have shown remarkable strength, rising nearly 80% so far this year. Greg acknowledged that while the market can be volatile with limited sellers, the goal is to attract more professional investors. The backing of Hannam & Partners is expected to bring in this new wave of buyers, helping to stabilize and potentially increase the share price further. Looking ahead, Greg remains optimistic about ticking all the necessary boxes leading up to a final investment decision by the end of the year. The company is focused on continued progress and delivering results that will pave the way for mine development. Conclusion Capital Metals is clearly on an exciting path as it advances the Taprobane Minerals Project. With strong drilling results, strategic partnerships, and a favorable investment climate, the company is building momentum toward its goal of becoming a significant player in Sri Lanka's resource sector. Stakeholders and observers alike will be watching closely as Capital Metals moves through the next critical phases of development. For more updates and in-depth interviews on mining and resource projects, follow Zak Mir's ongoing coverage and insights.

Hundreds of approved devices use artificial intelligence to help physicians diagnose patients faster and more accurately. Brooke & Associates is a legal and regulatory advisory firm that helps medical device makers get AI-powered devices through FDA pre-market approval.In Episode #40 of the MedTech Speed to Data podcast, Key Tech's Andy Rogers and Lei Zong speak with the firm's managing member, Jason Brooke, about the FDA's latest guidance to medical device developers for integrating AI into their products.Need to knowAI's role in MedTech — AI identifies otherwise undetectable data patterns that humans can apply in clinically meaningful ways.FDA's AI staffing surges — The agency accelerated hiring to develop internal AI applications and support pre-market reviews of new AI-powered devices.Radiological imaging leads the pack — More than half of 900+ FDA-approved AI-based products are in radiological imaging.Other fields are catching up — Cardiology and neurology applications are more recent entrants in AI-powered devices, but their numbers are growing.The nitty-grittyThe FDA published “Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations” in early 2025 to explain how it will address AI's adaptive nature in medical device regulation.“This guidance is really focused on a total product lifecycle approach,” Brooke explains.Good management practices govern traditional medical device development, so documenting the development process in pre-market submissions is not as critical. AI model development is different because the model can evolve once in service.“There's a level of information that's necessary in submissions for AI-based technologies that we haven't had to provide to the FDA before,” Brooke says. “They want a lot of information,” Brooke says. “That's an area I think may be problematic because a lot of that is somewhat trade secret.”AI-specific guidance touches almost every aspect of a company's submission, from risk assessment to labeling to cybersecurity. Brooke highlighted how the FDA's approach to AI data management could change development practices to ensure the independence of training and validation data sets. For example, companies must separate their clinical sites geographically and temporally.“This guidance gets into the weeds,” Brooke says. “It's important for companies to understand this if they're developing an AI-based product.”Data that made the difference:In addition to discussing the FDA's proposed AI regulations, Brooke discusses the challenges companies face in bringing AI-powered medical devices to market.“If you take away anything from this podcast,” Brooke says, “it's that there's a lot of burden associated with developing an AI-based medical device. If you don't need to, then I wouldn't recommend doing it.”Slow and steady wins the race. Do your homework, plan for the FDA review, and then engage the agency at the right time to get them on board.Thoroughly characterize your data sources. Devices like ECGs can vary by vendor, model, site location, patient, and many other factors. The FDA wants to know how this variability could affect the downstream AI model.Develop a strong clinical validation plan. The FDA will limit claims and require disclosures when a device that performs well overall underperforms among certain patient groups.

Welcome to Ask Stago, The Podcast dedicated to provide expert answers to your expert questions in coagulation. In this “back to basics” mini-series, Dr LaShanta Brice will discuss the clinical utility of the three most common parameters tested in the lab, the PT, APTT and Fibrinogen. Today we are going to cover the Prothrombin Time! We will discover why an order for a PT would be received by the lab, generally why the PT is used in practice and some emerging trends particularly when considering the INR clinic. Happy listening! Literature source: CLSI H47 One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test     Content is scientific and technical in nature. It is intended as an educational tool for laboratory professionals and topics discussed are not intended as recommendations or as commentary on appropriate clinical practice.

Episode: 3014 Measuring Almost Nothing.  Today, we measure almost nothing.

Rua Gold. announced the commencement of drilling at the Cumberland gold camp drill target. Maple Gold Mines reported initial assay results from the first five drill holes completed during the 10,000-metre winter drill campaign  at its 100%-owned Douay Gold Project in Québec. West Point Gold announced the most recent drill results from its ongoing drill program at the Tyro Main Zone of the Gold Chain Project in Arizona. GFG Resources announced a private placement of premium flow-through units to raise gross proceeds of up to C$2.5 million. Los Andes Copper is pleased to announce that the Company has expanded its land package by obtaining first-priority exploration claims over new areas within and adjacent to the current property boundaries for Los Andes' Vizcachitas copper project in Chile.This episode of Mining Stock Daily is brought to you by…Integra Resources. Integra is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.comThe Mining Stock Daily morning briefing is produced by Clear Commodity Network. It is distributed throughout the world through your podcast network of choice, and by our friends at the Junior Mining Network. 

Mike Burke, Director and VP of Corporate Development at Sitka Gold (TSX.V:SIG - OTCQB:SITKF - FRE:1RF) joins me to discuss the company's March 18th news release and the first drill hole from its fully funded 30,000-meter drill program at the RC Gold Project in Yukon. Hole 75, totaling over 715 meters, returned a significant number of visible gold occurrences - 130 in total - and marks a 70-meter step-out from a high-grade interval drilled last year.   Mike explains how this early-season hole is targeting deeper mineralization below the current open-pit resource to test underground potential. Hole 75 showed more visible gold than previous holes, and Hole 76 is now underway to go even deeper, potentially past 800 meters.   Assay results for Hole 75 are expected by mid to late April. The company plans to ramp up with multiple drills in May, increasing news flow through the summer.   The market responded positively to the visuals, despite no assays yet, reflecting a stronger sentiment for gold stocks and early exploration activity. With gold over $3,000/oz and a large drill program underway, Sitka Gold is entering its most active exploration season to date.   If you have any follow up questions for Mike please email me at Fleck@kereport.com.    Click here visit the Sitka Gold website to learn more about the Company.

Successful organ transplants depend on quickly getting donor organs to their recipients. MediGO, now part of CareDx, pioneered logistics technologies that help make these life-saving procedures more successful than ever.In Episode #39 of the MedTech Speed to Data podcast, Key Tech's Andy Rogers and Lauren Eskew speak with MediGO co-founder Dr. Joseph Scalea about how data led the startup to solve challenges in the organ donation supply chain.Need to knowAmerica's nationwide organ donor network — From Hawaii and Alaska to Puerto Rico, patients are on a nationwide waitlist for compatible donor organs.Organ donation used to be local — As recently as the 1990s, most organ transplants came from local Organ Procurement Organizations (OPOs), so long-distance transport was rare.Today's organ logistics are complex — Every organ donation requires a singular supply chain combining private or commercial aircraft and ground vehicles to link fifty-six OPOs with hospitals.The nitty-grittyA practicing transplant surgeon and currently the Vice Chair of Innovation in the Department of Surgery at the Medical University of South Carolina, Dr. Scalea has seen a dramatic improvement in the efficiency and survivability of organ transplants.Operations that once took hours are now routinely completed within an hour. At the same time, complication rates are at all-time lows. Many technological advances made these improvements possible, but Dr. Scalea saw opportunities in the organ transplant system's operations.“We have about twenty-four hours to move a human kidney from the donor hospital,” he explains. This tight turnaround led Dr. Scalea to explore the potential for drone delivery. “We were watching the [transportation] time go up,” he recalls. “We hypothesized that using drones to seamlessly go from the donor to the recipient hospital might allow the recipient side more flexibility to get better outcomes.”Data that made the difference:Data drove MediGO's decision-making and ultimately led to a pivot from drone to supply chain technology. “We fundamentally believe that this problem is worth solving for the community,” Dr. Scalea says, “so what data are required to make this a business? It was through a combination of customer discovery, key informant interviews, and a ton of research into the space.”Identifying the actual customer was key. “We initially focused on the transplant centers,” Dr. Scalea says, “and then fundamentally recognized the organ banks responsible for moving the organs were the right customers. Organ banks didn't see as much immediate value in the biotelemetry. What they needed was logistics.”From there, the MediGO team could understand their customers' financial concerns. “We needed to understand funds flow — how those customers get reimbursed for the work they do.”As a practicing surgeon, Dr. Scalea inherently understood the customer's customers. “I was very fortunate to be an active transplant surgeon while standing up MediGO. Every day, I'd go to the hospital and ask myself, ‘Where's the organ?' This problem was real.”“As our colleagues around the country read the research we were publishing, it became clear there was a groundswell of interest in this problem being solved.”

On this weeks episode Brendan sits down with Patrick Hannington, a professor in the School of Public Health at the University of Alberta. His interests are at the interface between animals, parasites, and freshwater environments, including Prussian carp, a species capable of gynogesis, a reproductive technique that involves cloning and sperm stealing!  Patrick and Brendan discuss Prussian Carp, eDNA assay development, genetics, and assay validation. Recently, Patrick and his research group have been working to develop and implement a decentralized environmental DNA surveillance network to inform our understanding of invasive species, like Prussian carp and invasive mussels, in Western Canada. You can check out his labs work here: https://www.ualberta.ca/en/public-health/research/faculty-features/hanington.html Check out his teams swimmer's itch page here: https://swimmersitch.info/    Main Point: Don't forget the value of basic science!   Get in touch with us! The Fisheries Podcast is on Facebook, Bluesky, and Instagram: @FisheriesPod  Become a Patron of the show: https://www.patreon.com/FisheriesPodcast Buy podcast shirts, hoodies, stickers, and more: https://teespring.com/stores/the-fisheries- podcast-fan-shop Thanks as always to Andrew Gialanella for the fantastic intro/outro music. The Fisheries Podcast is a completely independent podcast, not affiliated with a larger organization or entity. Reference to any specific product or entity does not constitute an endorsement or recommendation by the podcast. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by the hosts are those of that individual and do not necessarily reflect the view of any entity that those individuals are affiliated in other capacities (such as employers).

Ohio-based Avation Medical has developed a bioelectric wearable device for at-home treatment of overactive bladder, promising improved quality of life for patients suffering from the most common cause of incontinence and urinary urgency.In Episode #38 of the MedTech Speed to Data Podcast, Andy Rogers discusses the Vivally System, entrepreneurship, and more with Avation Medical co-founder Jill Schiaparelli.Need to KnowBioelectric medicine is an alternative to pharmaceuticals and surgery — Selectively stimulating the nervous system can enhance, control, or fix a function without the tradeoffs of other treatments. Overactive bladder is a prime candidate for bioelectric solutions — Forty-five million Americans have overactive bladder, with nine million preferring adult diapers to traditional treatments.Nitty GrittyAlthough not fully understood, overstimulation of nerves in the bladder wall produces spasms, creating an urge to urinate as often as thirty times a day in extreme cases.Few sufferers choose sacral nerve stimulation, the gold standard treatment, which requires a device implanted near the spine to stimulate nerves regulating bladder behavior.“The moment you say surgery, it complicates things.” Schiaparelli explains. “You need a physician who knows how to do it, you need a patient who's willing to have what could be a very extensive surgery, and you need a payer who's willing to pay for the surgery.”Drugs for overactive bladder have unwelcome side effects that cause most patients to drop out of the care pathway. “When you look at those dynamics,” Schiaparelli says, “it screams a need. Patients want something that takes surgery out of the equation, doesn't have the side effects of drugs, and is convenient.”Avation Medical's Vivally System is an ankle-worn device that indirectly stimulates the sacral nerve through the tibial nerve without surgery. The device measures responses to adjust its stimulation automatically in real-time.“This physiologic closed loop allows the patient to have personalized, effective therapy in just thirty minutes once a week,” Schiaparelli says.Data that made a differenceAs a serial entrepreneur, Schiaparelli has learned that success requires understanding and meeting the needs of three key stakeholders: the patient, the physician, and the payer:Overactive bladder patients dissatisfied with traditional treatments are an enormous market. Most physicians can only offer prescriptions for imperfect drug therapies that do not generate revenue for their practices. Payers don't like either option since surgery costs reach $40,000 while drugs require lifetime prescriptions.“Every area we checked into, it made sense. This technology in this market checked all those boxes to say there's a need. We thought this was a real opportunity to disrupt the market.”But success requires addressing the needs of other stakeholders, including regulators and investors.Regulators' expectations, for example, drove Avation Medical's decision to implement quality control processes while starting its first clinical trial. “We knew that was going to be very important because we planned to use the clinical trial with our FDA submission.”Aligning Avation Medical's investors' expectations was just as important, with each investment round supporting the next stage in development and commercialization.Schiaparelli takes a holistic perspective on a Med Tech startup's data strategy.“It's speed, absolutely,” Schiaparelli says, “but it's also intelligent data that speaks to the needs of all the people that you'll need to demonstrate to down the line.”

Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal management of this serious kidney disease.Speaker 3: (00:32) Would you mind telling us a little bit about yourself and your background? Speaker 3: (01:58) Would you give us an overview of membranous nephropathy?  Speaker 3: (07:14) Could you tell us a little bit about this new assay? Speaker 3: (14:29) Could you give a little example of how a clinician might use this information to treat their patients differently than how they would've in the past?   

Transforming Chronic Pain Treatment with a Lean, Data-focused Development StrategyBased in Washington, DC, AlgometRx has developed a technology platform that will let clinicians perform objective pain assessments to improve treatments for chronic pain.In Episode 37 of the MedTech Speed to Data Podcast, Key Tech's Andy Rogers and AlgometRx Chief Operating Officer Kevin Jackson discuss how collecting the right data sped the Nociometer platform's development.Need to knowPain diagnosis is challenging — Patients self-report their experience, which is inherently subjective and variable.Pain treatment involves trial and error — Finding the right treatment plan often requires a months-long iterative process.Risks of inappropriate drug treatments increase — Poor understanding of pain's causes leads to the over-prescription of the wrong drugs, a contributing factor to the opiate crisis.The nitty-grittyAlgometRx's technology platform emerged from research by the company's founder, Dr. Julia Finkel at Children's National Hospital. A pediatric anesthesiologist, Dr. Finkel must assess pain in children who lack the words to describe their experiences.“She wanted something that she could use in clinic to help better understand patients' pain,” Jackson explains. “Something that's simple enough that anyone could use in a variety of settings.”The Nociometer platform selectively activates nerve fibers and evaluates the patient's physical response — without causing additional pain.“We're able to identify the physiologic underpinnings of that pain experience, and that allows clinicians to better understand what's happening.”An objective assessment of the patient's pain lets the clinician make faster, better-informed decisions, but the real value will come from monitoring treatments. Rather than waiting three months to see if a treatment works, patients can return to the clinic a week later for a follow-up measurement. “That gives the clinician different information they wouldn't have had, Jackson says. “We can get right to the root of it, and you avoid six, seven, eight visits.”Data that made the difference:AlgometRx discussed this first-of-its-kind technology with the FDA before developing its proof-of-concept prototype. “We had this novel concept of a pain biomarker and device, so we wanted to know how we would even bring a device like this [to market].” FDA feedback informed a development strategy focused on gathering data from specific populations.AlgometRx leveraged partnerships to support this focused strategy. Working with Johns Hopkins researchers under an NIH Sprint for Women's Health grant, AlgometRx is developing pain response data sets for patients with systemic lupus and carpal tunnel syndrome. The startup is also a member of JLABS, Johnson & Johnson Innovation's life sciences incubator, where they get valuable insight into the Nociometer platform's potential role in pharmaceutical research.Running a lean operation lets AlgometRx prioritize data. Jackson is the startup's only full-time paid employee. Dr. Finkel, AlgometRx's board, and a network of consultants and contractors bring their expertise as needed. “We don't have a robust employee base, but we have a robust team,” Jackson says. “We've run this lean approach where we only bring in people as needed. Obviously, our investors love that idea because it's spending money on device development and data generation.”

In this episode of the Epigenetics Podcast, we talked with Vijay Ramani from the Gladstone Institute to talk about his work on Single-Molecule Adenine Methylated Oligonucleosome Sequencing Assay (SAMOSA). Our discussion starts with Vijay Ramani's impactful contributions to the field during his time in Jay Shendure's lab, where he worked on several innovative methods, including RNA proximity ligation. This project was conceived during his graduate studies, aiming to adapt techniques from DNA research to investigate RNA structures—a largely unexplored area at the time. We delved into the nuances of his experiences in graduate school, emphasizing how critical it was to have mentors who provided room for creativity and autonomy in experimental design. Dr. Ramani then shares insights about his foray into developing more refined methodologies, such as in-situ DNA Hi-C, a revolutionary protocol tailored for three-dimensional genomic mapping. He explained the rationale behind his projects, comparing the outcomes with contemporaneous advancements in methods like Micro-C. The discussion highlighted the importance of understanding enzyme bias in chromatin studies and the need for meticulous experimental design to ensure the validity of biological interpretations. We further explored exciting advancements in single-cell genomics, specifically Ramani's work on developing sci-Hi-C. This innovative technique leverages combinatorial indexing to allow high-resolution mapping of chromatin architecture at the single-cell level, a significant leap forward in understanding the complexities of gene regulation. As we progress, Ramani detailed his transition from graduate student to independent investigator starting his own lab. He elaborated on the challenges and excitements associated with establishing his research focus in chromatin structure and function using advanced sequencing technologies. Employing various strategies, including the innovative SAMOSA assay, his research seeks to elucidate the mechanisms by which chromatin structure influences transcriptional regulation. We also discussed the heterogeneity of chromatin and its implications for gene expression. Ramani provided a fascinating perspective on how variations in chromatin structure could affect gene activity, highlighting potential avenues for future research that aims to untangle the complex dynamics at play in both healthy and diseased states.   References Ramani, V., Cusanovich, D., Hause, R. et al. Mapping 3D genome architecture through in situ DNase Hi-C. Nat Protoc 11, 2104–2121 (2016). https://doi.org/10.1038/nprot.2016.126 Nour J Abdulhay, Colin P McNally, Laura J Hsieh, Sivakanthan Kasinathan, Aidan Keith, Laurel S Estes, Mehran Karimzadeh, Jason G Underwood, Hani Goodarzi, Geeta J Narlikar, Vijay Ramani (2020) Massively multiplex single-molecule oligonucleosome footprinting eLife 9:e59404. https://doi.org/10.7554/eLife.59404 Abdulhay, N.J., Hsieh, L.J., McNally, C.P. et al. Nucleosome density shapes kilobase-scale regulation by a mammalian chromatin remodeler. Nat Struct Mol Biol 30, 1571–1581 (2023). https://doi.org/10.1038/s41594-023-01093-6 Nanda, A.S., Wu, K., Irkliyenko, I. et al. Direct transposition of native DNA for sensitive multimodal single-molecule sequencing. Nat Genet 56, 1300–1309 (2024). https://doi.org/10.1038/s41588-024-01748-0   Related Episodes Epigenetic Mechanisms in Genome Regulation and Developmental Programming (James Hackett) Chromatin Profiling: From ChIP to CUT&RUN, CUT&Tag and CUTAC (Steven Henikoff) Split-Pool Recognition of Interactions by Tag Extension (SPRITE) (Mitch Guttman)   Contact Epigenetics Podcast on X Epigenetics Podcast on Instagram Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Epigenetics Podcast on Threads Active Motif on X Active Motif on LinkedIn Email: podcast@activemotif.com

Data drives MedTech growth, from the leanest startup to the world's most valuable pharmaceutical company. In Episode #36 of the MedTech Speed to Data Podcast, Key Tech's Andy Rogers discusses data-driven trends in medical technology with Anand Subramony, Eli Lilly's Vice President of Drug Delivery, Device, Connected Solutions & Innovation.Need to know·       Quarter-century perspective — After getting his PhD in chemistry and materials science from Purdue University, Subramony spent the next twenty-five years developing novel medical technologies for firms like Johnson & Johnson, Novartis, and AstraZeneca.·       Cutting-edge combination product development — Now at Eli Lilly, Subramony's team is responsible for combination product development, from early development through commercial development, for new delivery dosage forms.The nitty-grittySubramony drew upon his career-spanning perspective to discuss significant data-driven trends that impact the entire industry, not just Eli Lilly.One topic he raised in his conversation with Andy was using data to monitor disease state progression. Already an important element of fields like neurology and oncology, extensive data collection will become essential to a wider range of treatments. For many conditions, Subramony explains, disease state is a binary evaluation.“You can really understand disease state progression using digital biomarkers and collecting data throughout [the treatment],” Subramony said. “I think these are areas where there is a lot of potential.”Another data-driven trend Subramony discusses is the adoption of direct delivery therapies. When treating tumors and other conditions, off-target toxicity can cause unfortunate side effects. Genetic medicines, such as mRNA therapies, can target the cell surface, protect the cargo, and prevent endosomal escape.“It's going to disrupt the way we look at drug delivery from macroscopic pen auto-injector deliveries to microscopic, targeted deliveries where you need to take the therapeutic moiety into the site of action,” Subramony said.Data that made the difference:This episode's wide-ranging conversation covered many additional topics of interest to the MedTech community, including:GLP-1 treatments are “really transformative” for individual patients who can afford them. However, bringing costs down will depend on data demonstrating how lower obesity and healthier lifestyles reduce the overall burden on the healthcare system.For sensors and connected devices to go beyond “bells and whistles,” the industry must drive value from how we use that data. Relating compliance to efficacy, for example, makes moving patients from less effective to more effective therapies easier and faster.Continuous monitoring can improve healthcare outcomes but requires new data management practices to govern how much data is collected, who is collecting and viewing the data, and what are the privacy rules protecting patients. 

Interview with Troy Boisjoli, CEO of Atha Energy Corp.Our previous interview: https://www.cruxinvestor.com/posts/atha-energy-tsxvsask-north-americas-largest-uranium-exploration-portfolio-6037Recording date: 25th November 2024ATHA Energy, a uranium exploration company with an extensive land portfolio, is making strategic advancements in a market poised for significant growth. With over 8.5 million acres across Canada's premier uranium jurisdictions, including the Athabasca and Thelon Basins, ATHA's flagship Angilak project in Nunavut is at the forefront of its development strategy. The project has a historical resource of 43 million pounds (Mlbs) of uranium at an average grade of 0.69% U₃O₈, with exploration indicating the potential to expand that resource to an upper target of 98 Mlbs.The Angilak project is a standout asset, offering both scalability and development advantages. Located in Nunavut, a mining-friendly jurisdiction where 47% of GDP is mining-related, the project benefits from existing supply chains and infrastructure established by neighboring operators like Agnico Eagle. Unlike many deeper uranium deposits, Angilak's mineralization begins at or near the surface, reducing development complexity and costs. “At Angilak, [the resource] comes right to surface—it's sub-cropping,” noted ATHA CEO Troy Boisjoli, highlighting this key advantage.ATHA's leadership team brings extensive uranium experience, including expertise from Cameco and NexGen. Boisjoli, who served as Chief Geologist at Cameco's Eagle Point Mine, sees parallels between Angilak and his previous operations. He emphasized, “Eagle Point had a very similar profile to Angilak—70 million pounds remaining at 0.7%.” The team's capability spans early-stage exploration through to operational development, positioning ATHA to efficiently de-risk and scale its assets.The company employs a disciplined capital allocation strategy, directing 70% of its resources toward Angilak while investing the remaining 30% in discovery-stage projects like the Gemini property in Saskatchewan and other generative opportunities. This approach ensures near-term growth and a robust pipeline of future prospects, mitigating risks associated with reliance on a single project. Assay results from Gemini are expected in Q1 2025, adding another layer of potential upside.ATHA's timing aligns with a favorable uranium market. The industry is experiencing a resurgence, driven by long-term contracting cycles, growing nuclear energy adoption, and limited supply. As Boisjoli observed, “We're entering a long-term contracting cycle similar to 2006, when demand significantly outpaced supply and created upward pressure on uranium prices.” Recent production challenges from competitors like Paladin and Peninsula highlight the market's tightness and underscore the need for scalable, high-quality assets like Angilak.Angilak's exploration results further enhance its appeal. A 10,000-meter drill program conducted in 2023 demonstrated mineralization across all 25 holes, validating the resource's growth potential. Boisjoli emphasized ATHA's rigorous approach, which relies on hard data rather than speculative geophysical targets, ensuring confidence in the project's scalability.For investors, ATHA Energy presents a compelling case. With a flagship asset primed for resource expansion, a seasoned leadership team, and a disciplined approach to exploration and development, ATHA is well-positioned to capitalize on the growing uranium market. The combination of timing, expertise, and a diversified asset base offers a unique opportunity for those seeking exposure to this generational uranium opportunity.—Learn more: https://cruxinvestor.com/companies/atha-energySign up for Crux Investor: https://cruxinvestor.com

Andrew Pollard, President and CEO of Blackrock Silver (TSX.V:BRC – OTCQX:BKRRF), joins me to review the next batch of high-grade silver and gold intercepts returned from this year's expanded 22,000 meter Measured and Indicated (M&I) conversion drill program on the 100% controlled Tonopah West Project, in Nevada.  We also discuss the potential for expansion drilling, the rising grade profile, and timeline to permitting.   Highlights from this next batch of drill results:    TXC24-095 returned multiple zones of high-grade mineralization including: 1.68 meters of 1,056 grams per tonne (g/t) silver equivalent (AgEq) [572.7 g/t silver (Ag) and 5.38 g/t gold (Au)] from 192.9 meters 1.83 meters of 341 g/t AgEq (147 g/t Ag and 2.61 Au) from 196 meters 1.07 meters of 633 g/t AgEq (343.7 g/t Ag and 3.21 Au) from 239 meters, including 0.55 meters of 1,225 g/t AgEq (665 g/t Ag and 6.23 g/t Au) and 5.03 meters of 774.5 g/t AgEq (461.5 g/t Ag and 3.47 g/t Au) from 242.5 metres, including 0.76 meters of 2,245 g/t AgEq (1,362 g/t Ag and 9.8 g/t Au) TXC24-098 returned 1.22 meters of 634 g/t AgEq (265.6 g/t Ag and 4.09 g/t Au) from 326.8 meters, including 0.3 meters of 2,480 g/t AgEq (1,034 gt Ag and 16.06 g/t Au) TXC24-117 returned 2.01 meters of 1,783 g/t AgEq (1,141 g/t Ag and 7.13 g/t Au) from 261.2 meters, including 0.4 meters of 6,064.4 g/t AgEq (3,712 g/t Ag and 26.13 g/t Au)   Andrew discusses how the goals of this drill program are to improve confidence in the continuity of mineralization in the deposit, converting Inferred mineralized areas Measured and Indicated, while connecting orphaned areas of mineralization, including the potential of bringing in the 12 million ounces of stranded ounces at the Northwest Step Out.  Additionally, there is the goal to increase the resources and anticipated mine life a few years beyond the 8-year and 8.6 million annual production that was first outlined in the Preliminary Economic Assessment (PEA).   In that initial PEA at the base case gold price of $1,900 per ounce and silver price of $23 per ounce, the Project commands an after-tax net present value (“NPV”) discounted at 5% of $326-million on a low initial capex of $178-million (including $22-million contingency) with a payback of 2.3 years and an after-tax internal rate of return (“IRR”) of 39.2%, and an All-in Sustaining Costs (“AISC”) of $11.96 per silver equivalent ounce basis.   One of the other takeaways from the last two batches of drill results released is that the grade profile is actually increasing, with many results coming in higher than the average resource grade previously released to the market, and thus should be improving the economics as well.   Andrew outlines that the plan is to keep drilling through 2024 into the first half 2025, and then updating the resources and PEA accordingly.    We wrap up having Andrew walk us through the advantages of being on private land in Nevada, the anticipated permitting timeline, and some of the improving sentiment for US-based projects under the Trump administration, which may offer more blue-sky upside on the surround BLM prospects in their land package.  He feels their resources, preliminary economics, permitting path and ability to grow puts the Tonopah West Project in a unique position to separate from most other silver projects in the space, and potentially be attractive as an acquisition target to larger producers.     If you have any follow up questions for Andrew regarding Blackrock Silver, then please email us at Fleck@kereport.com or  Shad@kereport.com.   For full disclosure, Shad is shareholder of Blackrock Silver at the time of this recording.   Click here to visit the Blackrock Silver website to read over the recent news we discussed.

Alpha-synuclein plays a key role in the pathophysiology of Parkinson's disease, and researchers have been investigating this protein as a therapeutic target and also as a potential biomarker for the disease. The alpha-synuclein seed amplification assay, developed by Dr. Claudio Soto and colleagues, leverages the self-replicating nature of the misfolded alpha-synuclein proteins that form aggregates in Parkinson's disease. Amplifying misfolded alpha-synuclein can allow researchers and clinicians to detect the presence of the pathological form of the protein in biospecimens, even when the amount of misfolded alpha-synuclein in a sample is very low. In this episode, Claudio discusses his work in this area and how it has opened the doors for a variety of potential uses of the alpha-synuclein seed amplification assay, including applications in diagnosis, clinical trials, and drug development for Parkinson's disease.This year, Claudio received the 2024 Robert A. Pritzker Prize for Leadership in Parkinson's Research for his substantial contributions to research and his commitment to mentoring the next generation of scientists in the field. Claudio is the Huffington's Distinguished University Chair, Professor of Neurology, and Director of the George and Cynthia Mitchell Center for Alzheimer's Disease and Related Brain Disorders at The University of Texas Medical School in Houston. He is also the Founder, Vice-President, and Chief Scientific Officer at AMPRION Inc.This podcast is geared toward researchers and clinicians. If you live with Parkinson's or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson's Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

Alpha-synuclein plays a key role in the pathophysiology of Parkinson's disease, and researchers have been investigating this protein as a therapeutic target and also as a potential biomarker for the disease. The alpha-synuclein seed amplification assay, developed by Dr. Claudio Soto and colleagues, leverages the self-replicating nature of the misfolded alpha-synuclein proteins that form aggregates in Parkinson's disease. Amplifying misfolded alpha-synuclein can allow researchers and clinicians to detect the presence of the pathological form of the protein in biospecimens, even when the amount of misfolded alpha-synuclein in a sample is very low. In this episode, Claudio discusses his work in this area and how it has opened the doors for a variety of potential uses of the alpha-synuclein seed amplification assay, including applications in diagnosis, clinical trials, and drug development for Parkinson's disease.This year, Claudio received the 2024 Robert A. Pritzker Prize for Leadership in Parkinson's Research for his substantial contributions to research and his commitment to mentoring the next generation of scientists in the field. Claudio is the Huffington's Distinguished University Chair, Professor of Neurology, and Director of the George and Cynthia Mitchell Center for Alzheimer's Disease and Related Brain Disorders at The University of Texas Medical School in Houston. He is also the Founder, Vice-President, and Chief Scientific Officer at AMPRION Inc.This podcast is geared toward researchers and clinicians. If you live with Parkinson's or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson's Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

Cell therapy research and manufacturing are driving demand for automated high-throughput equipment to improve quality, reduce costs, and shorten the development cycles of innovative treatments that save lives. But what factors shape a startup's journey from the lab to commercialization?In Episode #35 of the Speed to Data podcast, Key Tech Business Development Manager Kelly Parker leads a panel of industry experts who discuss high-throughput automation in cell therapy screening and manufacturing.Daniela Hristova-Neeley, Ph.D., is a partner at the advisory firm Health Advances, where she is a leader in the diagnostics and life sciences tools practice.Blair Morad is Senior Director of Engineering at Cellino, a startup developing autonomous biomanufacturing technology for personalized cell therapies.Nova Syed is a founder and angel investor in the deep tech and healthcare sector. Most recently, Syed was the founding VP of Product at Mekonos, a developer of silicon nano-needles for cell therapies.Need to knowThree factors drive requirements in cell therapy screening:·       Customers are studying a huge variety of biological systems and drug targets. ·       Business requirements drive the need for faster and cheaper therapy development.·       Meeting regulatory standards demands high-quality, reproducible data.In manufacturing, meeting GMP makes design requirements even more complex as the product must:·       Improve flexibility and scalability.·       Improve quality control and traceability.·       Lower manufacturing costs.·       Reduce human interaction to improve efficiency and quality.The nitty-grittyGiven the many competing business, market, and regulatory requirements, the instrument design process inevitably forces developers to make tradeoffs.The panelists agreed that quality is table stakes, which means technologists and business leaders must balance time, cost, and scope.“You have to be ruthless when it comes to prioritizing your differentiator,” Hristova-Neeley said.In Morad's experience, understanding the organization's core competency is essential to focusing on the right problems.Data that made the differenceThe three panelists shared their lessons learned from hard experience in the healthcare technology business.Get early feedback from the market. “Product-market fit doesn't just happen,” Syed explains. “Unless you get feedback directly from the users and the customers, you don't have the data to iterate to the next cycle.”Hristova-Neeley agreed. “It's always important to hear what the customers have to say. Automation is certainly important, but it's not the only thing that is going to solve how we do cell therapy manufacturing or cell therapy development.”Look for outside expertise. “When you're working with the right experts,” Morad said, “they know how to ask the right questions that are helpful to move forward.” A good startup employs many intelligent people, but they won't know everything about everything. Find outside partners who have already built the assays, workflows, automation modules, and other elements outside your core competency so you can focus on your innovations.

The horseshoe crab has endured for over 450 million years. It has survived several mass extinctions including the one that killed off the dinosaurs. One reason for their incredible resiliency is their ability to fend off bacterial infection. Their blood contains cells that clot around invading bacteria, thereby protecting them from the attacking toxins.In this episode we talk with three experts about how this animal's unique blue blood has become essential to modern medicine. We also talk about why horseshoe crab populations are dwindling, and what biotech is doing to address the shortfall.Follow us on LinkedIn, X, Facebook and Instagram. Visit us at https://www.bio.org/

Past Discussions

INDEX: 00:00 - Introduction 02:41 - Exploration and drilling update 04:21 - Assay results and timeline 05:46 - Case Lake cesium uniqueness 09:08 - Drill results and geology 11:13 - First Nation partnership update 13:39 - Timeline to production 14:57 - Cesium advisory committee formed 16:42 - Grant funding details 18:33 - Closing remarks   _________________________________________________   Links

Earlier this year, renovations on Boise's historic Assay Office began. As the construction crew broke ground though they discovered they were digging up more than just dirt.

The RID-MyC assay, a CRISPR/Cas12a-based test, offers swift and reliable detection of Fungal Keratitis, enhancing diagnostic capabilities at point-of-care settings. Dr. Rajesh Rao interviews Dr. Siddharth Narendran on the development of this assay from his Ophthalmology Science article, “Development and Clinical Evaluation of a CRISPR/Cas12a-Based Nucleic Acid Detection Platform for the Diagnosis of Keratomycoses.” Development and Clinical Evaluation of a CRISPR/Cas12a-Based Nucleic Acid Detection Platform for the Diagnosis of Keratomycoses. Deivarajan, Hanith Raj et al. Ophthalmology Science, Volume 4, Issue 5. Join Ophthalmology's Editor-in-Chief, Russell Van Gelder, as he presents “The Year in Literature: Editor's Choice Highlights From the Ophthalmology Journal Family”  in Chicago at AAO 2024 on Sunday October 20, 2024, at 2pm local time in McCormick Place South Building Room S406A. Search “SYM48” in the Mobile Meeting Guide for more information.

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

In this episode, we review the high-yield topic of⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Enzyme-Linked Immunosorbent Assay (ELISA)⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Immunology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

Golden Cariboo Resources (CSE: GCC | OTCQB: GCCFF | WKN: A0R2CQ | FSE: 3TZ) has received assay results from drill holes at their flagship Quesnelle Gold Quartz Mine property. The company is exploring for gold in the Barkerville Gold Belt in British Columbia, Canada.In this interview, President and CEO Frank Callaghan discusses the assay results and provides exploration updates at the Quesnelle Project. He confirms that Golden Cariboo's main worksite is safe from the recent forest fires in northern Alberta. Frank also talks about Golden Cariboo's market performance and future plans during the interview.Check out Golden Cariboo Resources and its Quesnelle Gold Quartz Mine property: https://goldencariboo.comWatch the full YouTube interview here: https://youtu.be/vTFwNWOx8D4And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1

District Metals provides an update on their land position in Sweden, particularly the Viken deposit, which contains uranium, vanadium, and other metals. The lifting of the uranium moratorium in Sweden is being investigated, and there is a possibility that a proposed bill will go to parliament this fall. District Metals plans to update the preliminary economic assessment (PEA) on the Viken deposit to include vanadium and potash. They may also drill metallurgical holes and convert some inferred resources into indicated. District Metals is considering applying for a listing on the NASDAQ First North Growth Market in Sweden to increase liquidity and allow Swedish investors to participate. Assay results from the Tomtebo property are expected to be released soon.

American Eagle Gold CEO, Anthony Moreau, provides an update on the drilling progress at the NAK porphyry project in British Columbia. The company has added a second drill rig and has drilled over 800 meters so far. Assay results are pending, but the core samples look promising. Moreau discusses the potential depth of the drilling and the cost considerations. He also highlights the significance of hole 19, which is drilling into unexplored territory.

Red Pine Exploration is back in the news with a new batch of recently drilled assays from the Wawa Gold Project. NexGen Energy says drilling at Patterson Corridor East has intersected 67.5m of mineralization. CanAlaska Uranium reported new assay results from the Pike Zone. FPX Nickel has appointed Scott Larson as the new President and Chief Executive Officer of CO2 Lock. GFG Resources will kick off their new drill campaign at the Goldarm property. This episode of Mining Stock Daily is brought to you by...  Arizona Sonoran Copper Company (ASCU:TSX) is focused on developing its brownfield copper project on private land in Arizona. The Cactus Mine Project is located less than an hour's drive from the Phoenix International airport. Grid power and the Union Pacific Rail line situated at the base of the Cactus Project main road. With permitted water access, a streamlined permitting framework and infrastructure already in place, ASCU's Cactus Mine Project is a lower risk copper development project in the infrastructure-rich heartland of Arizona.For more information, please visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.arizonasonoran.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Fireweed Metals is advancing 3 different projects within the Yukon and Northwest Territories, including the flagship Macmillan Pass Project, a large zinc-lead-silver deposit and the Mactung Project, one of the largest and highest-grade tungsten deposits in the world. Fireweed plans to advance these projects through exploration, resource definition, metallurgy, engineering, economic studies and collaboration with indigenous people on the path to production. For more information please visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠fireweedmetals.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Victoria Gold operates the Eagle Gold Mine within the Dublin Gulch Property. Eagle is the largest gold mine in Yukon's long history of gold production. In addition to the long-life Eagle Gold Mine, the Dublin Gulch property has upsized exploration potential including priority targets Raven and Lynx among others. Follow all the gold production and exploration news at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠vgcx.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

Paul Jannetto, Ph.D., explains the advantages that Mayo Clinic Laboratories' oral fluid drug screening offers over typical urine tests. Oral samples are easier to collect and harder to adulterate.(00:32) Can you tell us a little bit about yourself and your background? (01:46) Can you please provide an overview of laboratory testing for substance use disorders and specifically Mayo Clinic's new oral fluid controlled substance monitoring option? (03:47) Which patients should have this testing and when should it be performed? (05:16) What alternative test options are available and how do these compare? (06:31) How are the results used in patient care?

In this morning's briefing: Koryx Copper delivered assay results from Haib project, southern Namibia; Amex Exploration advanced geological understanding on Perron project, Quebec; Red Pine Exploration announced assay results from Wawa project, Ontario; Golden Arrow Resources is now drilling at the San Pietro Iron-Copper-Gold-Cobalt Project; and, Cosa Resources complete drilling program at Ursa project, Sask. This episode of Mining Stock Daily is brought to you by...  Arizona Sonoran Copper Company (ASCU:TSX) is focused on developing its brownfield copper project on private land in Arizona. The Cactus Mine Project is located less than an hour's drive from the Phoenix International airport. Grid power and the Union Pacific Rail line situated at the base of the Cactus Project main road. With permitted water access, a streamlined permitting framework and infrastructure already in place, ASCU's Cactus Mine Project is a lower risk copper development project in the infrastructure-rich heartland of Arizona.For more information, please visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.arizonasonoran.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Fireweed Metals is advancing 3 different projects within the Yukon and Northwest Territories, including the flagship Macmillan Pass Project, a large zinc-lead-silver deposit and the Mactung Project, one of the largest and highest-grade tungsten deposits in the world. Fireweed plans to advance these projects through exploration, resource definition, metallurgy, engineering, economic studies and collaboration with indigenous people on the path to production. For more information please visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠fireweedmetals.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at ⁠https://vizslasilvercorp.com/⁠ Victoria Gold operates the Eagle Gold Mine within the Dublin Gulch Property. Eagle is the largest gold mine in Yukon's long history of gold production. In addition to the long-life Eagle Gold Mine, the Dublin Gulch property has upsized exploration potential including priority targets Raven and Lynx among others. Follow all the gold production and exploration news at ⁠vgcx.com⁠.

In this morning's briefing: Western Alaska Minerals announced an increased brokered offering of up to $7 million; Filo Corp. announced assay results (yesterday) from eight holes from the Filo del Sol Project; Probe Gold announced the final set of results (28 holes) from Monique Val-d'Or, Quebec; Summa Silver provide assay results from its final two drill holes at Mogollon, New Mexico; and, Freegold Ventures announce drill start at Golden Summit. This episode of Mining Stock Daily is brought to you by...  Arizona Sonoran Copper Company (ASCU:TSX) is focused on developing its brownfield copper project on private land in Arizona. The Cactus Mine Project is located less than an hour's drive from the Phoenix International airport. Grid power and the Union Pacific Rail line situated at the base of the Cactus Project main road. With permitted water access, a streamlined permitting framework and infrastructure already in place, ASCU's Cactus Mine Project is a lower risk copper development project in the infrastructure-rich heartland of Arizona.For more information, please visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.arizonasonoran.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Fireweed Metals is advancing 3 different projects within the Yukon and Northwest Territories, including the flagship Macmillan Pass Project, a large zinc-lead-silver deposit and the Mactung Project, one of the largest and highest-grade tungsten deposits in the world. Fireweed plans to advance these projects through exploration, resource definition, metallurgy, engineering, economic studies and collaboration with indigenous people on the path to production. For more information please visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠fireweedmetals.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at ⁠https://vizslasilvercorp.com/⁠ Victoria Gold operates the Eagle Gold Mine within the Dublin Gulch Property. Eagle is the largest gold mine in Yukon's long history of gold production. In addition to the long-life Eagle Gold Mine, the Dublin Gulch property has upsized exploration potential including priority targets Raven and Lynx among others. Follow all the gold production and exploration news at ⁠vgcx.com⁠.

Aaron Moncur interviews Dylann Ceriani about her career in mechanical engineering and medical devices. They discuss prototype injection molding, material selection, 3D printing applications, and advice for young engineers.Main Topics:Career journey from biomechanics to founding ProtoShopDifferences between production and prototype molding  Cost considerations and timelines for prototype toolingAdvances in medical device development and regulationsTips for minimizing molding costs and selecting materialsAdvice for advocating for yourself and learning from all experiencesAbout the guest: Dylann Ceriani is a distinguished figure in the field of mechanical engineering and the co-founder and principal mechanical engineer at Protoshop Inc. With a rich background in biomechanical engineering from the University of California, Berkeley, Dylann has carved a niche in the medical device industry, showcasing her expertise in product development, particularly in in-vitro diagnostics (IVDs) and orthopedics. Her career spans over 25 years, marked by a deep commitment to innovation, quality, and efficiency in engineering design. At Protoshop, Dylann leads the charge in revolutionizing prototype tooling, emphasizing the replication of production mold quality in prototypes. Her hands-on approach and strength-based leadership have not only advanced medical device product development but also inspired a generation of engineers. Links:Dylann Cerian - LinkedIn ProtoShop Inc WebsiteAbout Being An Engineer The Being An Engineer podcast is a repository for industry knowledge and a tool through which engineers learn about and connect with relevant companies, technologies, people resources, and opportunities. We feature successful mechanical engineers and interview engineers who are passionate about their work and who made a great impact on the engineering community. The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment such as cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us on the web at www.teampipeline.us

Episode: 3014 Measuring Almost Nothing.  Today, we measure almost nothing.